pipeline

Surrenti R&D in novatione coviD-19 feruntur, curationes cancer, plenae doloris imperium et morborum autoimmunem.

Clavis Programs indication Preclinical tempus te Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs  

COVISTIX™ (diagnostic) Celeri Antigen Test

*

Subitis Usus LICENTIA (EUA) in Mexico (COFEPRIS), Brasilia (ANVISA), CE Signata in Europa

COVIMARK™ (diagnostic) Celeri Antigen Test

*

Applicationem summitto in US et in Canada ad tumultuarios usus LICENTIA (EUA)

COVISHIELD™ (curatio) Neutralizing Antibody (IN) in outpatients et Inpatients

40%*

COVISHIELD™ (curatio) Neutralizing Antibody (IV) in Outpatients et Inpatients

20%*

FUJOVEE™ (Abivertinib) Gravis COVID-19 in ICU aegroti

82%*

Pivotal Trial nibh FDA Clearance

OQORY™ (COVI-MSC) ARDS ex COVID-19 in ICU aegroti

82%*

Pivotal Trial in Brasilia

MPro Inhibitor (oris pill) Anti-virales

40%*

Omicron mRNA Vaccine vaccine

20%*

Clavis Programs indication Preclinical tempus te Phase II Phase III/Pivotal FDA Approval
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) prostatae

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

* In societate cum Lee Pharm in China

PD-L1 (STI-3031)** Ceruicis cancer

82%*

** In US et in societate cum ImmuneOncia in Korea

CD47 solidus Tumors

40%*

CD38 DAR-T Herpesvirus multiple

40%*

CD38 ADC Amyloidosis, Myeloma multiplex, T-ALL, et gulae

40%*

TROP2 ADC* solidus Tumors

40%*

* In China

Seprehvec™ virus oncolyticum Solidi tumores; CNS Tumors

40%*

BCMA ADC Liquid Tumors

20%*

Bevacizumab-ADNAB™ Cancer endometrialis

40%*

In societate cum Mayo Clinic

Bevacizumab-ADNAB™ ovarian cancer

40%*

In societate cum Mayo Clinic

Rituximab-ADNAB™ B-cellula Lymphomas

40%*

In societate cum Mayo Clinic
Clavis Programs indication Preclinical tempus te Phase II Phase III/Pivotal FDA Approval
Phau:  

ZTlido™ 1.8%
Postherpetica Neuralgia - PHN

99.8%*

SP-102 (SEMDEXA) Radicularis lumborum / Dolor Ciatica

82%*

SP-103 (Lidocaine Topical System 5.4%) Acutus Back Pain

20%*

SP-104 (Burst Dilatio Minimum Dose Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Iniectio epiduralis
Dolor intractabilis in Cancer Advanced

60.3%*

Pupillus designatio

RTX (resiniferatoxin)
Iter intra-articular
Moderari ut Gravi genu OA Dolor

60.2%*

Clavis Programs indication Preclinical tempus te Phase II Phase III/Pivotal FDA Approval
Lymphatica Delivery  

Sofusa® TNF anti- Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-CTLA-4 Carcinoma

40%*

In societate cum Mayo Clinic
COVID-19 Programs
Clavis Programs (Indicatio) tempus
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
COVISHIELD™ (curatio) PH I
COVISHIELD™ (curatio) Preclinical
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (oralis pill) (anti-virales) Ph I
Omicron mRNA Vaccine (vaccine) Preclinical
immunotherapy
Clavis Programs (Indicatio) tempus
FUJOVEE™ (Abivertinb) (NSCLC) Ph III
FUJOVEE™ (Abivertinb) (B Cell Lymphomas) Ph II
FUJOVEE™ (Abivertinb) (Prostatae) Preclinical
FUJOVEE™ (Abivertinb) (Lupus) Preclinical
FUJOVEE™ (Abivertinb) (MS) Preclinical
FUJOVEE™ (Abivertinb) (GvHD) Preclinical
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Ceruicis cancer) Ph III
CD47 (Solidi tumores) Ph I
CD38 DAR-T (Multiplex Myeloma) Ph I
CD38 ADC (Amyloidosis, Myeloma multiplex, T-ALL, et oesophagealis) Ph I
TROP2 ADC* (Solidi tumores) Ph I
Seprehvec™ virus oncolyticum (Solidi tumores; CNS Tumors) PH I
BCMA ADC ( Liquida tumores ) Preclinical
Bevacizumab-ADNAB™ (Cancer endometrial) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Phau:
Clavis Programs (Indicatio) tempus
ZTlido™ 1.8% (Postherpetica Neuralgia - PHN) FDA Approval
SP-102 (SEMDEXA) Ph III
SP-103 (Lidocaine Topical System 5.4%) Preclinical
SP-104 (Burst Dilatio Minimum Dose Naltrexone) Preclinical
RTX (resiniferatoxin) iniectio epiduralis (Intractabilis Dolor in Cancer Advanced) Ph II
RTX (resiniferatoxin) iter intra-articular (Moderare ad genua doloris OA Gravi) Ph II
Lymphatica Delivery
Clavis Programs (Indicatio) Phase II
Sofusa® TNF anti- (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cuteous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-CTLA-4 (Carcinoma) Ph I